To top
Unit
ANA-MARIA LENNON DUMENIL / OLIVIER LANTZ
Immunity and Cancer (U932)

Created in 2005, the INSERM U932 Unit is composed of 10 teams, spread over two buildings (Hôpital Curie and Constant-Burg building, rue Lhomond), with a total of about 120 people.

 

Key figures
334
publication since 2017
11
ERC since 2008
3
start-ups
Key publications
All publications
News
All news
Scientific events
16 Sep
2024
Seminar Immunology series
11h-23h
When Nuance Matters: The lesser known side of PD1 signaling
The inhibitory immunoreceptor PD1 is a major cancer immunotherapy target. Anti-PD1 blockade antibodies have become the standard of care for cancer patients, but the low response rate and associated immune related side effects necessitate a better understanding of PD1 mechanism. Best known to be expressed by T cells, PD1 transduces inhibitory signals to attenuate T cell response upon binding to its
10 Sep
2024
Seminar
14h-23h
“B cell memory in barrier tissues” - " From the bench to the bedside: cancer immunotherapy with soluble T cell receptors"
B cell memory in barrier tissues

During infection, the immune system unleashes protective responses to fight against the pathogen while also establishes a memory compartment that will provide protection in case of a subsequent pathogen encounters. The B cell memory compartment is composed of two layers: long-lived plasma cells (LLPCs) and memory B cells (MBCs). LLPCs mainly migrate to the bone
10 Jun
2024
Seminar
11h-23h
Functional and molecular characterization of cancer-derived extracellular vesicles
Cancer-derived extracellular vesicles have been demonstrated to play a crucial role in cancer biology. Our team is particularly interested in cancer EV heterogeneity and we have been studying a particular population of extracellular vesicles, known as large oncosomes. These EVs are released by aggressive cancer cells that exhibit cell plasticity and have acquired metastatic abilities.  I will
21 May
2024
Seminar
11h-23h
Nucleosomes and DNA methylation – implications for immunodeficiency-centromeric instability-facial anomalies (ICF) syndrome and cancers
DNA methylation is a broadly observed epigenetic modification. As genomic DNA methylation profiles dynamically change during development and aging, alterations in DNA methylation patterns are linked to diseases such as cancers and immunodeficiency. ICF syndrome is characterized by hypomethylation at heterochromatin. Of four proteins whose mutation cause ICF syndromes (DNMT3B, ZBTB24, CDCA7 and HEL
13 May
2024
Seminar
11h-23h
“Deconstruct-Reconstruct” – Decode cancer-immune crosstalk & probe with organoids.
The Roose team at UCSF studies mechanisms of cell-cell interactions in immunology and cancer1-7, with emphasis on personalized medicine4,8 and single cell approaches9-11. Over the past 7 years, we shifted a large portion of our research efforts to understanding human biology and disease. We are deeply interested in the cellular networks that underpin autoimmune diseases and cancer, which I will ta
All scientific events
Job offers
No job offers available.
All job offers